



Catalyst Pharmaceuticals, Inc.
Investor Relations Department
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CPRX ¹

Last Trade:	3.79
Trade Time:	4:00 PM ET 01/18/18
Change:	-0.03 (0.785%)
Day Range	3.73 - 3.83
52-Week Range	1.03 - 4.51
Volume	202,700
Market Cap. (\$M)	388.361
Shares Out (M)	102.470

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse® is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 11/30/17 [Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Public Offering](#)
- 11/28/17 [Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock](#)
- 11/27/17 [Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock](#)
- 11/27/17 [Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome](#)
- 11/21/17 [Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy \(SMA\)](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- 03/15/17 [Annual Report \(10-K\)](#)
- 04/14/17 [Definitive Proxy Statement](#)
- 11/08/17 [Quarterly Report \(10-Q\)](#)
- 08/09/17 [Quarterly Report \(10-Q\)](#)
- 05/10/17 [Quarterly Report \(10-Q\)](#)